IRF2BP2 and neoplasm: Dorand et al. (2016) observed an IRF-2 and IRF2BP2 increase in CD4 T cells deficient in Cdk5, a serine–threonine kinase that is highly active in many cancers and important in immune evasion of tumor cells.